Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) have earned an average rating of “Moderate Buy” from the six brokerages that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $55.40.

Separately, Oppenheimer lowered their target price on Pelthos Therapeutics from $66.00 to $64.00 and set an “outperform” rating on the stock in a report on Friday, August 14th.

Insider Buying and Selling at Pelthos Therapeutics

In other Pelthos Therapeutics news, Director Todd C. Davis acquired 35,948 shares of Pelthos Therapeutics stock in a transaction dated Thursday, June 11th. The stock was bought at an average cost of $27.82 per share, with a total value of $1,000,073.36. Following the completion of the transaction, the director owned 75,834 shares of the company’s stock, valued at $2,109,701.88. The trade was a 90.13% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 1,638 shares of company stock valued at $43,107 over the last three months. 16.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Pelthos Therapeutics

Several large investors have recently bought and sold shares of PTHS. Persistent Asset Partners Ltd grew its position in Pelthos Therapeutics by 150.0% in the 4th quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock worth $186,000 after purchasing an additional 3,604 shares during the last quarter. Millennium Management LLC acquired a new position in shares of Pelthos Therapeutics during the fourth quarter valued at about $343,000. Pale Fire Capital SE raised its position in shares of Pelthos Therapeutics by 59.5% during the first quarter. Pale Fire Capital SE now owns 12,919 shares of the company’s stock valued at $271,000 after buying an additional 4,819 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Pelthos Therapeutics by 31.9% in the fourth quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock valued at $422,000 after buying an additional 3,295 shares during the period. Finally, Knott David M Jr lifted its stake in shares of Pelthos Therapeutics by 215.5% in the fourth quarter. Knott David M Jr now owns 19,281 shares of the company’s stock valued at $598,000 after buying an additional 13,169 shares during the period. 77.96% of the stock is currently owned by institutional investors and hedge funds.

Pelthos Therapeutics Stock Down 1.1%

Pelthos Therapeutics stock opened at $24.73 on Friday. The company has a debt-to-equity ratio of 3.40, a current ratio of 1.98 and a quick ratio of 1.31. Pelthos Therapeutics has a fifty-two week low of $18.19 and a fifty-two week high of $37.50. The firm has a fifty day moving average price of $27.17 and a two-hundred day moving average price of $25.26. The firm has a market cap of $94.72 million, a price-to-earnings ratio of -1.13 and a beta of 3.10.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($6.62) earnings per share (EPS) for the quarter. Pelthos Therapeutics had a negative net margin of 165.24% and a negative return on equity of 204.71%. The business had revenue of $15.60 million during the quarter. As a group, analysts forecast that Pelthos Therapeutics will post -15.22 earnings per share for the current year.

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).